Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD
Open Access
- 15 June 2026
- journal article
- research article
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (6) , 1215-1221
Abstract
Background: Glucagon-like-peptide-1 (GLP-1) agonists are beneficial for glycaemic control, weight loss, and cardiovascular health. Because GLP-1 agonists may be a useful tool in the management of obesity in patients with congenital heart disease (CHD), we examined whether GLP-1 agonists are effective and safe for weight loss in adults with congenital heart disease (ACHD) and explored the effects of sex and CHD complexity. Methods: We conducted a retrospective cohort study of ACHD patients who were prescribed a GLP-1 agonist from 1/1/2022–3/31/2024 at Yale New Haven Hospital. Patients were subdivided by CHD anatomic complexity. The primary outcome was the change in weight over time. Side effects were explored as a secondary outcome. Results: The moderate complexity ACHD group had the fastest weight loss during both the first 6 months and 12 months of treatment, but was comparable to the other two ACHD complexities in the full period of follow-up. Patients in the simple and great complexity groups required 12 months of treatment to reach meaningful weight loss. Females had a faster rate of weight loss compared to males across all ACHD complexity levels. The most common side effects reported were gastrointestinal, such as nausea, acid reflux, and diarrhoea. Conclusion: This study provides evidence that GLP-1 agonists are effective for weight loss in ACHD patients, with the greatest weight loss in females and patients with moderate ACHD complexity. Moreover, GLP-1 agonists in the ACHD population have a reasonable side effect profile that is typical for these agents.Keywords
This publication has 20 references indexed in Scilit:
- Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart DiseaseJACC: Advances, 2025
- Prevalence of obesity among adult patients with congenital heart disease: A population-based studyInternational Journal of Cardiology, 2025
- Safety and Efficacy of GLP-1 Agonists in a Cohort of Patients with Fontan CirculationPediatric Cardiology, 2024
- Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trialsDiabetologia, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort studyObesity, 2023
- Sizing Up Fontan Failure: Association with Increasing Weight in AdulthoodPediatric Cardiology, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Obesity across the lifespan in congenital heart disease survivors: Prevalence and correlatesHeart & Lung, 2020
- Extracardiac complications of the Fontan circuitPediatric Radiology, 2011